Weiss Multi-Strategy Advisers’s Xenon Pharmaceuticals XENE Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,000	Closed	-$230K	–	489
2023 Q4	$230K	Buy	+5,000	New	+$177K	0.01%	507
2023 Q2	–	Sell	-54,140	Closed	-$1.94M	–	778
2023 Q1	$1.94M	Buy	+54,140	New	+$2M	0.05%	427
2017 Q3	–	Sell	-31,500	Closed	-$99K	–	635
2017 Q2	$99K	Hold	31,500	–	–	﹤0.01%	502
2017 Q1	$126K	Hold	31,500	–	–	0.01%	525
2016 Q4	$243K	Hold	31,500	–	–	0.01%	375
2016 Q3	$255K	Sell	31,500 -900	-3%	-$6.95K	0.02%	384
2016 Q2	$191K	Sell	32,400 -18,600	-36%	-$128K	0.01%	377
2016 Q1	$356K	Buy	51,000 +6,000	+13%	+$43.1K	0.02%	406
2015 Q4	$362K	Buy	45,000 +2,600	+6%	+$22.3K	0.02%	317
2015 Q3	$350K	Buy	+42,400	New	+$421K	0.02%	343

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Weiss Multi-Strategy Advisers's XENE Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Xenon Pharmaceuticals (XENE) in Q1 2024, closing a stake of 5,000 shares — an estimated $230K sold.

Weiss Multi-Strategy Advisers first reported a position in XENE in Q3 2015 and held it in 10 quarters. The position peaked at $1.94M in Q1 2023. 220 funds tracked by Wall St. Rank hold XENE as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Xenon Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 5,000 Xenon Pharmaceuticals shares in Q1 2024, an estimated $230K.
Weiss Multi-Strategy Advisers first reported a position in Xenon Pharmaceuticals in Q3 2015 and held it in 10 quarters.
Weiss Multi-Strategy Advisers's Xenon Pharmaceuticals position peaked at $1.94M in Q1 2023.
220 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.